Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Second Booster BNT162b2 Restores SARS-CoV-2 Humoral Response in Patients With Multiple Myeloma, Excluding Those Under Anti-BCMA Therapy
Ioannis Ntanasis‐Stathopoulos, Vangelis Karalis, Maria Gavriatopoulou, et al.
HemaSphere (2022) Vol. 6, Iss. 8, pp. e764-e764
Open Access | Times Cited: 25

Showing 25 citing articles:

Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN)
Evangelos Terpos, Pellegrino Musto, Monika Engelhardt, et al.
Leukemia (2023) Vol. 37, Iss. 6, pp. 1175-1185
Open Access | Times Cited: 33
Humoral response after a fourth dose of SARS-CoV-2 vaccine in immunocompromised patients. Results of a systematic review
Silvia Martinelli, Domenico Pascucci, Patrizia Laurenti
Frontiers in Public Health (2023) Vol. 11
Open Access | Times Cited: 20
Convalescent Plasma Therapy for COVID-19: A Systematic Review and Meta-Analysis on Randomized Controlled Trials
Charalampos Filippatos, Ioannis Ntanasis‐Stathopoulos, Kalliopi Sekeri, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 765-765
Open Access | Times Cited: 16
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 15
Efficacy and safety of daratumumab with ixazomib and dexamethasone in lenalidomide‐exposed patients after one prior line of therapy: Final results of the phase 2 study DARIA
Evangelos Terpos, Ioannis Ntanasis‐Stathopoulos, Maria Gavriatopoulou, et al.
American Journal of Hematology (2024) Vol. 99, Iss. 3, pp. 396-407
Open Access | Times Cited: 5
Follow-up of humoral and cellular immune responses after the third SARS-CoV-2 vaccine dose in multiple myeloma patients
Vincenzo Raimondi, Paola Storti, Rosanna Vescovini, et al.
Frontiers in Immunology (2025) Vol. 16
Open Access
Use of Oral Antivirals Ritonavir-Nirmatrelvir and Molnupiravir in Patients with Multiple Myeloma Is Associated with Low Rates of Severe COVID-19: A Single-Center, Prospective Study
Vassiliki Spiliopoulou, Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, et al.
Viruses (2023) Vol. 15, Iss. 3, pp. 704-704
Open Access | Times Cited: 11
Low Spike Antibody Levels and Impaired BA.4/5 Neutralization in Patients with Multiple Myeloma or Waldenstrom’s Macroglobulinemia after BNT162b2 Booster Vaccination
Margherita Rosati, Evangelos Terpos, Jenifer Bear, et al.
Cancers (2022) Vol. 14, Iss. 23, pp. 5816-5816
Open Access | Times Cited: 16
Survival in multiple myeloma and SARS‐COV‐2 infection through the COVID‐19 pandemic: Results from the EPICOVIDEHA registry
Pellegrino Musto, Jon Salmanton‐García, Nicola Sgherza, et al.
Hematological Oncology (2023) Vol. 42, Iss. 1
Open Access | Times Cited: 9
Clinical usefulness of testing for severe acute respiratory syndrome coronavirus 2 antibodies
Harry Alexopoulos, Ioannis P. Trougakos, Meletios Α. Dimopoulos, et al.
European Journal of Internal Medicine (2022) Vol. 107, pp. 7-16
Open Access | Times Cited: 15
Real-World Effectiveness and Safety of Belantamab Mafodotin Monotherapy in Triple-Class Refractory Multiple Myeloma
Ioannis Ntanasis‐Stathopoulos, Panagiotis Malandrakis, Despina Fotiou, et al.
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 14, pp. 11829-11829
Open Access | Times Cited: 8
Long term follow-up of humoral and cellular response to mRNA-based vaccines for SARS-CoV-2 in patients with active multiple myeloma
Katia Mancuso, Elena Zamagni, Vincenza Solli, et al.
Frontiers in Oncology (2023) Vol. 13
Open Access | Times Cited: 6
Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians
Tommaso Lupia, Lorenzo Cani, Sara Bringhen, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 9, pp. 592-603
Closed Access | Times Cited: 1
Examining the immunological responses to COVID-19 vaccination in multiple myeloma patients: a systematic review and meta-analysis
Hamid Harandi, Parisa Fallahtafti, Amirali Karimi, et al.
BMC Geriatrics (2024) Vol. 24, Iss. 1
Open Access | Times Cited: 1
Impact of homologous and heterologous boosters in neutralizing antibodies titers against SARS-CoV-2 Omicron in solid-organ transplant recipients
Aracelly Gaete-Argel, Vicente Saavedra-Alarcón, Denis Sauré, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Immune Reconstitution and Vaccinations in Multiple Myeloma: A Report From the 19th International Myeloma Society Annual Workshop
Evangelos Terpos, Paola Neri, Niels W.C.J. van de Donk, et al.
Clinical Lymphoma Myeloma & Leukemia (2023) Vol. 23, Iss. 6, pp. 413-419
Closed Access | Times Cited: 4
Humoral and cellular immune responses after three or four doses of BNT162b2 in patients with hematological malignancies
Line Dam Heftdal, Sebastian Rask Hamm, Laura Pérez‐Alós, et al.
European Journal Of Haematology (2023) Vol. 111, Iss. 2, pp. 229-239
Open Access | Times Cited: 3
COVID-19 in multiple myeloma patients: frequencies and risk factors for hospitalization, ventilatory support, intensive care admission and mortality –cooperative registry from the Grupo Brasileiro de Mieloma Multiplo (GBRAM)
Márcia Garnica, Edvan Crusoé, Glaciano Ribeiro, et al.
Hematology Transfusion and Cell Therapy (2023) Vol. 46, Iss. 2, pp. 153-160
Open Access | Times Cited: 3
Tixagevimab/Cilgavimab as Pre-Exposure Prophylaxis against COVID-19 for Multiple Myeloma Patients: A Prospective Study in the Omicron Era
Ioannis Ntanasis‐Stathopoulos, Charalampos Filippatos, Maria Gavriatopoulou, et al.
Diseases (2023) Vol. 11, Iss. 3, pp. 123-123
Open Access | Times Cited: 3
Clinical outcome of breakthrough COVID-19 in multiple myeloma patients after three or more anti-SARS-CoV-2 vaccine doses: a single center analysis of 64 cases
Nicola Sgherza, Paola Curci, Rita Rizzi, et al.
Annals of Hematology (2023) Vol. 103, Iss. 1, pp. 351-355
Closed Access | Times Cited: 3
Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma
Gaurav Agarwal, Sally Moore, Ross Sadler, et al.
Haematologica (2024)
Open Access
Humoral and cellular immune response to second and third severe acute respiratory syndrome coronavirus 2 mRNA vaccine in patients with plasma cell dyscrasia
Tomotaka Suzuki, Shigeru Kusumoto, Yoshiko Kamezaki, et al.
Cancer Medicine (2023) Vol. 12, Iss. 12, pp. 13135-13144
Open Access | Times Cited: 1
COVID-19 vaccination in patients with cancer: Opportunities and challenges
Zahraa Haleem Al‐qaim, Hasanain Kamil Hasan Owadh, Sarah A. Ali, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 2
Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
María Rescigno, Chiara Agrati, Carlo Salvarani, et al.
medRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Humoral and cellular BNT162b2 mRNA-based booster vaccine-induced immunity in patients with multiple myeloma and persistence of neutralising antibodies: results of a prospective single-centre cohort study
Tobias Silzle, Christian R. Kahlert, Werner C. Albrich, et al.
Schweizerische medizinische Wochenschrift (2023) Vol. 153, Iss. 6, pp. 40090-40090
Open Access
Page 1

Scroll to top